Orforglipron Approved: The First Oral GLP-1 Pill and What It Means for Peptide Research

The FDA approved Eli Lilly's orforglipron in June 2026 — the first oral smallmolecule GLP1 receptor agonist for obesity and type 2 diabetes. Unlike injectable semaglutide and tirzepatide, orforglipron requires no injection, potentially expanding access to GLP1 therapy significantly.

For research use only. Not for human consumption.